Clinical Trial Update: Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and efficacy of a dual PI3K Delta/Gamma inhibitor in T-cell lymphoma types; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Peripheral T-cell Lymphoma
• T-cell Lymphoma

Drugs mentioned

• Dual PI3K Delta/Gamma Inhibitor

Snippet

Sponsor: Rhizen Pharmaceuticals SA | Conditions: Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous | Phase 1 | Status: COMPLETED | Results posted: 2020-01-13